logo
  • Home
  • Solution
  • Impact
  • R&D
    • Science
    • Publications
    • STEP study
  • About
    • Team and Board
  • News and Events
    • All News
    • All Events
    • All Press Releases
  • Contact

Approved clinical trial application for BioC gel on complex wounds

19 October, 2022
|In News
|By Helene Hartman

The CTA (Clinical Trial Application) has been approved by the Swedish Medical Products Agency (Läkemedelsverket) and the Ethics committee. The study will include patients with large complex wounds and the aim is to show safety and tolerability.

Recent Posts

  • Xinnate får FDAs Fast Track-status för TCP-25 vid behandling av epidermolysis bullosa
  • Xinnate receives FDA Fast Track Designation for TCP-25 for the Treatment of Epidermolysis Bullosa
  • The 3rd World Congress on Rare Skin Diseases: 01-03 July 2026
  • BIO International Convention: 22-25 June 2026
  • EADV Symposium 2026: 07-09 May 2026

Archives

  • June 2026
  • May 2026
  • February 2026
  • January 2026
  • December 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • January 2025
  • December 2024
  • September 2024
  • May 2024
  • March 2024
  • February 2024
  • March 2023
  • October 2022
  • September 2022
  • July 2022
  • March 2022
  • August 2021
  • October 2020
  • January 2020
  • Prev
  • Next
© 2026 Xinnate. All rights reserved